<DOC>
	<DOCNO>NCT01348516</DOCNO>
	<brief_summary>The purpose study investigate safety pharmacokinetics KM-023 single/multiple dosing .</brief_summary>
	<brief_title>Single Ascending Dose ( SAD ) /Multiple Ascending Dose ( MAD ) Safety/Pharmacokinetic ( PK ) Study KM-023</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Subject inform investigational nature study voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent prior perform screen procedure Male female 20 45 year age time screening , inclusive A subject body weight ≥ 45 kg body mass index ( BMI ) 18.5 25 ( inclusive ) . BMI ( kg/m2 ) = weight ( kg ) / { height ( ) } 2 Capable give write informed consent , include compliance requirement restriction list consent form . Able understand comply protocol requirement , instruction protocolstated restriction . 1 . A subject history allergy drug ( aspirin , antibiotic , etc . ) , history clinically significant allergy 2 . A subject clinical evidence history hepatic ( include carrier hepatitis virus ) , renal , respiratory , endocrine , neurologic , immunologic , hematologic , oncologic , psychiatric , cardiovascular disease 3 . A subject history gastrointestinal disease surgery ( except simple appendectomy repair hernia ) , influence absorption study drug 4 . A female subject pregnant , nurse mother , sexually active female ( childbearing potential ) 5 . Patients take following medication ; Bepridil , cisapride , midazolam , pimozide , triazolam , Ergot medication ( e.g . Wigraine , cafergot , St. John 's wort ) , Phenobarbitol 6 . Patients previously demonstrate hypersensitivity Efavirenz one component Stocrin Sustiva 7 . A positive Hepatitis B surface antigen positive Hepatitis C antibody screen . 8 . A positive test HIV antibody ( per local practice ) 9 . A subject take prescribed medication herbal compound within 14 day prior study drug administration . In addition , subject take overthecounter drug vitamin supplement within 7 day prior study drug administration . 10 . A subject participate clinical trial either investigational market drug within 8 week study drug administration 11 . A subject donated loss ≥ 400 mL blood within 8 week prior start administration study drug 12 . The value aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 1.25 time upper limit reference range . 13 . A subject unable abstain drink alcoholic beverage throughout study period . 14 . A subject history drug abuse , positive urine drug screen test 15 . A subject heavily take caffeine caffeinecontaining product , take grapefruit , grapefruit juice , grapefruitcontaining product 16 . A subject unable eat standardize meal offer study center 17 . A subject previously assign treatment study ( except take study medication ) 18 . Systolic blood pressure outside range 80 140 mm Hg , diastolic blood pressure outside range 60 85 mm Hg , heart rate outside range 50 100 beat per minute ( bpm ) females ; outside range 45 100 beat per minute ( bpm ) male subject . Blood pressure heart rate take 10 minute rest . 19 . The investigator judge subject eligible study review clinical laboratory result reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HIV</keyword>
</DOC>